PRVA Privia Health
- 18.030
- -0.830-4.40%
Privia Health News
Buy Rating Reaffirmed for Privia Health Group Amid Strong Financial Performance and Positive Growth Outlook
Privia Health Shares Are Trading Lower After the Company Reported a Q1 Revenue Miss.
Privia Health Shares Are Trading Lower After the Company Reported a Q1 Revenue Miss.
Privia Health | 10-Q: Quarterly report
Privia Health Group Adjusted Earnings, Revenue Rise in Q1; Offers Full Year 2024 Revenue Guidance
Privia Health Group (PRVA) reported Q1 earnings Thursday of $0.18 per share, up from $0.16 a year earlier. Analysts polled by Capital IQ expected $0.15. Revenue for the quarter ended March 31 was $415
Privia Health Reiterates FY24 Guidance; Revenue Of $1.6B-$1.675B, Est $2.844B
Privia Health Reiterates FY24 Guidance; Revenue Of $1.6B-$1.675B, Est $2.844B
Privia Health Gr Q1 2024 Adj EPS $0.18 Beats $0.05 Estimate, Sales $415.243M Miss $679.999M Estimate
Privia Health Gr (NASDAQ:PRVA) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.05 by 260 percent. This is a 12.5 percent increase over earnings of $0.16
Earnings Flash (PRVA) PRIVIA HEALTH GROUP Reports Q1 EPS $0.18, Vs. Street Est of $0.15
06:07 AM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (PRVA) PRIVIA HEALTH GROUP Reports Q1 EPS $0.18, vs. Street Est of $0.15
Press Release: Privia Health Reports First Quarter 2024 Financial Results
Privia Health Reports First Quarter 2024 Financial Results -- Practice Collections +7.4% compared to 1Q'23 -- Implemented Providers +17.3% compared to 1Q'23 -- Company Reiterated Full Year 2
Privia Health 1Q Rev $415.2M >PRVA
Privia Health 1Q Rev $415.2M >PRVA
Stifel Nicolaus Reaffirms Their Buy Rating on Privia Health Group (PRVA)
Privia Health Is Maintained at Buy by Stifel
Privia Health Is Maintained at Buy by Stifel
Stifel Maintains Buy on Privia Health Gr, Lowers Price Target to $24
Stifel analyst Craig Jones maintains Privia Health Gr (NASDAQ:PRVA) with a Buy and lowers the price target from $28 to $24.
Privia Health Initiated at Buy by Citigroup
Privia Health Initiated at Buy by Citigroup
Citigroup Initiates Coverage On Privia Health Gr With Buy Rating, Announces Price Target of $25
Citigroup analyst Daniel Grosslight initiates coverage on Privia Health Gr with a Buy rating and announces Price Target of $25.
Barclays Sticks to Its Hold Rating for Privia Health Group (PRVA)
Privia Health Group, Inc. (NASDAQ:PRVA) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Privia Health Group (NASDAQ:PRVA) has had a rough month with its share price down 15%. However, stock prices are usually driven by a company's financials over the long term, which in this case look
Privia Health to Report First Quarter 2024 Results on Thursday, May 9
Canaccord Genuity Adjusts Privia Health Group Price Target to $37 From $41, Maintains Buy Rating
Privia Health Group (PRVA) has an average rating of Buy and price targets ranging from $21 to $37, according to analysts polled by Capital IQ.
Privia Health Is Maintained at Buy by Canaccord Genuity
Privia Health Is Maintained at Buy by Canaccord Genuity
Canaccord Genuity Maintains Buy on Privia Health Gr, Lowers Price Target to $37
Canaccord Genuity analyst Richard Close maintains Privia Health Gr (NASDAQ:PRVA) with a Buy and lowers the price target from $41 to $37.
Analysis
Price Target
No Data
